DeMoss v. City Market, Inc.

762 F. Supp. 913, 1991 U.S. Dist. LEXIS 4715, 1991 WL 59327
CourtDistrict Court, D. Utah
DecidedMarch 21, 1991
DocketCiv. 90-C-461W
StatusPublished
Cited by10 cases

This text of 762 F. Supp. 913 (DeMoss v. City Market, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
DeMoss v. City Market, Inc., 762 F. Supp. 913, 1991 U.S. Dist. LEXIS 4715, 1991 WL 59327 (D. Utah 1991).

Opinion

MEMORANDUM DECISION AND ORDER

WINDER, District Judge.

This matter is before the court on defendant Showa Denko K.K.’s motion to dismiss plaintiff’s Amended Complaint for lack of personal jurisdiction and for insufficient service of process. A hearing on the motion was held March 15, 1991. Showa Denko K.K. was represented by Tracy H. Fowler, William H. Christensen and John M. Bredehoft. Defendant City Market, Inc. was represented by Scott W. Christensen. Plaintiff was represented by Douglas B. Cannon. Before the hearing, the court considered carefully the memoranda and other materials submitted by the parties in relation to the motion. Since taking the matter under advisement, the court has *915 further considered the law and facts relating to this motion. Now being fully advised, the court renders the following memorandum decision and order.

BACKGROUND

Showa Denko K.K. (“SDK”) is a Japanese corporation headquartered in Tokyo, Japan. Since 1982, SDK, as a regular part of its business, synthesized and sold L-tryp-tophan, an amino acid, for human consumption. Plaintiffs complaint alleges that in 1989 she purchased and ingested in Utah contaminated L-tryptophan manufactured by SDK. As a result of that L-tryptophan ingestion, plaintiff alleges she developed an extremely painful and debilitating blood disorder known as eosinophilia-myalgia syndrome (“EMS”).

Plaintiff alleges that defendants Showa Denko America, Inc. (“SDA”), a wholly owned subsidiary of SDK; City Market, Inc., and Every Life, Inc., were involved in the chain of distribution, marketing and sale of some or all of the L-tryptophan ingested by plaintiff. Neither City Market nor Every Life directly purchased L-trypto-phan from SDA or SDK.

SDK has no offices, bank accounts, debts, real property or leases in the United States. SDK did not market or advertise L-tryptophan for sale in Utah nor did it place advertisements for L-tryptophan in any national publication. SDK’s only direct contacts with Utah occurred in 1988 and 1989 when SDK employees visited the state on four separate occasions for business purposes unrelated to L-tryptophan.

SDK owns a direct or indirect interest in three United States corporations: Showa Denko Carbon, Inc., a Delaware corporation; Showa Aluminum Corporation of America, an Ohio corporation; and SDA, a New York corporation. SDA’s principal place of business is in New York and it maintains offices in California and Illinois. SDK has one seat on SDA’s three-member Board of Directors. The meetings of the SDA Board of Directors are held in New York and the minutes of those meetings are kept in English. SDA has 14 employees and about $100,000 in fixed assets, composed primarily of office fixtures and a one-room apartment.

SDA served as SDK’s exclusive United States distributor of L-tryptophan. In 1989, SDK supplied approximately 50 to 60 percent of the L-tryptophan consumed in the United States, which represented 68 percent of SDK’s worldwide L-tryptophan sales. SDK’s worldwide sale of L-trypto-phan constituted approximately $7 million of $3.62 billion in total sales, or approximately .2 percent of SDK’s total sales.

SDK sold the L-tryptophan to SDA in 50-kilogram fiber drums, which SDA in turn sold to distributors and formulators who processed the material into capsules and tablets for wholesale distribution. SDA’s shipments of L-tryptophan in 1989 were made to customer locations in New Jersey, New York, Michigan, South Carolina, California, Connecticut, Florida, Illinois and Oregon. In 1987, SDA sold a single 50-kilogram bulk shipment of L-tryptophan to a company located in Ogden, Utah. SDA has made no other sales of bulk L-tryptophan to any other customer in Utah.

SDK was not involved in the distribution or processing of L-tryptophan after deliveries of the product were accepted by SDA. SDK did work with SDA, however, in the marketing and developing of SDK products, including L-tryptophan, destined for distribution in the United States. In addition, SDK personnel made occasional visits to the United States to meet with SDA’s L-tryptophan customers.

On November 13, 1989, after learning of a possible link between EMS and L-trypto-phan consumption, SDK requested that SDA immediately cease further sales of L-tryptophan. SDA last shipped L-trypto-phan on November 9, 1989, and, on November 20, 1989, SDA recalled unprocessed bulk L-tryptophan from its customers.

STANDARD OF REVIEW

Plaintiff bears the burden of establishing personal jurisdiction over the defendant. Taylor v. Phelan, 912 F.2d 429, 431 (10th Cir.1990) (quoting Behagen v. *916 Amateur Basketball Ass’n of U.S.A., 744 F.2d 731, 733 (10th Cir.1984), cert. denied, 471 U.S. 1010, 105 S.Ct. 1879, 85 L.Ed.2d 171 (1985)). Prior to trial, when a motion to dismiss for lack of personal jurisdiction is decided on the basis of affidavits and other written materials, plaintiff need only make a prima facie showing of jurisdiction. Id. at 431. In assessing whether this standard has been met, allegations in the complaint that are uncontroverted by defendant’s affidavits must be taken as true and all factual disputes are resolved in plaintiffs favor. Id.

DISCUSSION

A. Service of Process

During oral argument on this motion, counsel for plaintiff and defendant informed the court that plaintiff intended to effect proper service of process upon defendant pursuant to Article 5 of the Hague Convention on Service Abroad of Judicial and Extrajudicial Documents in Civil or Commercial Matters, 20 U.S.T. 361, T.I.A.S. 6638, reprinted in 28 U.S.C.A. following Fed.R.Civ.P. 4. (“Hague Service Convention”). Accordingly, the court need not and does not address the issue whether plaintiff’s attempted service of process by registered mail violated the Hague Service Convention. Because the affidavit of Tak-ahisa Sugano was submitted solely in support of defendant’s insufficiency of service argument, plaintiff’s motion to strike the affidavit of Mr. Sugano is moot and the court does not reach it.

B. Personal Jurisdiction

Whether this court may exercise personal jurisdiction over a nonresident defendant in a diversity action is determined by the law of the forum state and the requirements of the due process clause of the fourteenth amendment to the United States Constitution. Taylor v. Phelan, 912 F.2d 429, 431 (10th Cir.1990). This determination involves a two-step analysis. First, the court must determine whether a state statutory basis exists to assert jurisdiction over the defendant. Second, if jurisdiction is proper under the statute, the court must determine whether exercising such jurisdiction comports with the requirements of due process. See Taylor, 912 F.2d at 431; Lister v. Marangoni Meccanica S.P.A.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Arguello v. Industrial Woodworking MacHine Co.
838 P.2d 1120 (Utah Supreme Court, 1992)
Vermeulen v. Renault, U.S.A. Inc.
965 F.2d 1014 (Eleventh Circuit, 1992)
Vermeulen v. Renault
965 F.2d 1014 (Eleventh Circuit, 1992)
Phone Directories Co., Inc. v. Contel Corp.
786 F. Supp. 930 (D. Utah, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
762 F. Supp. 913, 1991 U.S. Dist. LEXIS 4715, 1991 WL 59327, Counsel Stack Legal Research, https://law.counselstack.com/opinion/demoss-v-city-market-inc-utd-1991.